Relay Therapeutics Revenue and Competitors

Claim your profile

Boston, MA USA



Total Funding



Estimated Revenue & Valuation

  • Relay Therapeutics's estimated annual revenue is currently $47.3M per year.(i)
  • Relay Therapeutics received $400.0M in venture funding in December 2018.
  • Relay Therapeutics's estimated revenue per employee is $155,000
  • Relay Therapeutics's total funding is $520M.

Employee Data

  • Relay Therapeutics has 305 Employees.(i)
  • Relay Therapeutics grew their employee count by 54% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Relay Therapeutics is building the world's first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. By placing protein motion at the heart of drug discovery, Relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. Headquartered in Cambridge, Mass., Relay Therapeutics is a private company launched in 2016. To date, Relay Therapeutics has raised $120M in financing from Third Rock Ventures, BVF Partners, GV (formerly Google Ventures), an affiliate of D.E. Shaw Research, Casdin Capital, EcoR1 Capital, Section 32 and Alexandria Venture Investments. Our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you're creative, collaborative and passionate about making a difference in the lives of patients, join us!



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Relay Therapeutics News

2020-07-16 - Relay Therapeutics prices IPO at $400M

Relay initially filed to go public with the Securities and Exchange Commission on June 25, stating that it was looking to raise $200 million. It had completed a Series C venture capital funding round worth $400 million in December 2018. Since that round, it has already started to move its produc ...

2021-04-16 - RELAY THERAPEUTICS, INC. Relay Therapeutics Extends Leadership in Integrating Computational and Experimental Approaches to Create Precision Medicines by Acquiring ZebiAI

Relay Therapeutics’ leadership in this new breed of biotech positions the company as a strategic partner of choice for emerging technologies and founders in these fields ZebiAI amplifies Relay Therapeutics’ Dynamo™ platform with a library of industry-leading experimental DEL data sets and valid ...

2021-10-08 - Relay Therapeutics : Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα - Form 8-K

Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα RLY-2608 preferentially binds mutant PI3Kα at a novel allosteric site discovered by the Dynamo™ platform Preclinically, achieved tumor regressions in vivo w ...

09/03/2019 - Biotech IPO and M&A predictions from Jefferies analyst ...

More about Compass Therapeutics: The biotech company makes drugs ..... Relay Therapeutics: The Cambridge, Massachusetts-based biotech ...

09/08/2019 - Surges in R&D Jobs, VC Propel Massachusetts Biopharma ...

... three nine-figure deals: Moderna's pre-IPO $500 million in equity financing, completed in February 2018; Relay Therapeutics' $400 million in ...

09/03/2019 - Biopharma jobs boom in Massachusetts, though challenges ...

Moderna Therapeutics and Relay Therapeutics are both headquartered in Cambridge, and are responsible for the two biggest venture capital ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Relay Therapeutics Funding

DateAmountRoundLead InvestorsReference
2016-09-15$57.0MAThird Rock Ventures, LLCArticle
2017-12-15$63.0MBBVF PartnersArticle
2018-12-21$400.0MCSoftBank Vision FundArticle